AUDUBON, Pa.--(BUSINESS WIRE)--Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, and the worldwide leader in expandable interbody technology, today announced the launch of ALTERA™, the first new minimally invasive fully articulating expandable spacer for spinal fusion. Designed for restoring lordosis and maintaining sagittal balance while reducing the challenges of insertion, the spacer is inserted at a minimized height, articulated into an anterior position, and then expanded vertically to optimize fit. The company is showcasing ALTERA™ as well as several recently launched products at the North American Spine Society (NASS) Annual Meeting, being held in San Francisco this week, Booth #1119.
ALTERA™ is the latest addition to Globus’ industry leading family of expandable spacers, and delivers the benefits of minimized insertion height, continuous expansion and optimized fit. Because of the articulation into anterior placement and the option for 8° or 15° profile angles, ALTERA™ optimizes lordosis compared to standard static transforaminal lumbar interbody fusion (TLIF) crescent-shaped spacers. Additionally, ALTERA™ allows for in-situ delivery of autogenous bone graft into, as well as around, the implant after it has been expanded.
“Globus has led the way with our growing portfolio of transformative, disruptive technologies; we have had great reception and ongoing success with our CALIBER®, RISE®, CALIBER®-L, LATIS™, and MONUMENT™ interbody cages. Each of these implants along with ALTERA™ offers a better solution over traditional cages, be it a simplified procedure, tailored and optimized fit, or ease of insertion with minimal impaction. We are excited about the prospects for ALTERA™, which is the fourth new disruptive TLIF expandable technology we’ve launched in as many years for Globus,” commented Andrew Iott, Senior Vice President of Product Development.
“This is a big improvement over other TLIF cages available today. The steerable articulaton and vertical expansion of ALTERA™, tailoring lumbar balance and proper posture without the need for successive trialing, is a game-changer. The ability to completely pack the expanded graft window through a separate port creates optimal fusion conditions,” commented Dr. Paul K. Kim, Neurosurgeon at Carolina Neurosurgery and Spine Associates.
Indications
The ALTERA™ Spacer is an interbody fusion device intended for use in patients with degenerative disc disease (DDD) at one or two contiguous levels of the lumbosacral spine (L2-S1). DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had at least six (6) months of non-operative treatment. In addition, these patients may have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). The ALTERA™ Spacer is to be filled with autogenous bone graft material. These devices are intended to be used with supplemental fixation.
About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at www.globusmedical.com.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
